Latest news with #FRA
Business Wire
6 hours ago
- Business
- Business Wire
Belgravia Hartford Announces Additional Bitcoin Purchases and Growing Bitcoin Treasury
TORONTO--(BUSINESS WIRE)--BELGRAVIA HARTFORD CAPITAL INC. (CSE:BLGV)(OTC:BLGVF)(FRA:ECA) (' Company ' or ' Belgravia ') is pleased to announce it has completed two further Bitcoin (' BTC ') purchases enhancing the value and credibility of Belgravia's Bitcoin treasury strategy. Belgravia increases Bitcoin treasury position. Belgravia Treasury Bitcoin Purchase Belgravia today announces that it has used cash-on-hand, derived from the exercise of previously issued convertible securities by shareholders to purchase an additional 1.5316351 BTC for a total purchase price of USD $160,842.59 at an average price of USD $105,013.65 per BTC inclusive of all costs and fees. This results in Belgravia's total BTC treasury now totaling 6.39316479 BTC at an average cost of USD $103,367.05 per BTC. The purchases were again made via Coinsquare's regulated OTC trading desk with Company funds and not funded through the previously announced USD $5 million credit facility (the Facility) provided by Round13 Digital Asset Fund L.P. (Round13 DAF) for the Belgravia BTC treasury acquisitions as previously announced on May 28, 2025. The Company intends to continue using the Facility when determined in the best interests of the Company and its shareholders. Mehdi Azodi, CEO of Belgravia stated: 'We remain fully engaged with Round 13 DAF our strategic advisors, we will collaborate closely to determine the best times to drawdown on the Facility as well as when to use Belgravia's own capital – including future financing options and opportunities as we pursue our 100% BTC treasury strategy.' Mr. Azodi continued, 'As a micro-cap, we have determined regularly adding BTC to the balance sheet is our best use and store of funds, and that such activity is currently imperative for accretive growth in shareholder value. We will continue to drawdown on the Facility where needed, but these recent purchases were with Company funds. We intend to continue using Company funds for BTC purchases by way of ongoing cash injections from the exercise of existing and already issued convertible securities.' Bitcoin Advisory Team Belgravia is also pleased to announce the appointment of Mr. Joey Cacciatore as Director of Bitcoin Strategy. Mr. Cacciatore brings deep conviction and a long-term vision to Belgravia's Bitcoin treasury mandate, further strengthening the leadership in digital asset strategy. Mr. Cacciatore's family owns and operates Lakeside Bank, a respected financial institution based in Chicago, bringing additional financial insight and credibility to Belgravia and the Bitcoin-focused capital strategy. Mehdi Azodi further commented: 'Mr. Cacciatore's credibility and extensive network across the financial and media sectors represent a valuable asset to Belgravia, I am delighted to welcome Mr. Cacciatore to Belgravia's Bitcoin advisory team.'
Zawya
10 hours ago
- Business
- Zawya
Egypt: FRA extends submission deadlines for insurance companies' financial statements
Arab Finance: The Financial Regulatory Authority (FRA) has issued decision No. 126 of 2025 extending the deadlines for submitting periodic financial statements for insurance companies and insurance pools, as per a statement. This comes as part of ongoing efforts to ease procedural requirements and support sector growth. The decision, issued by the FRA's board of directors under the chairmanship of Mohamed Farid, applies to financial periods ending in March, June, and September 2025. Specifically, the submission deadline for statements covering the period ending March 31st, 2025, has been extended by one month to July 30th, 2025. For the period ending June 30th, 2025, the deadline has been extended by 15 days to September 15th, 2025. Similarly, the deadline for the period ending September 30th, 2025, has been extended by 15 days to December 15th, 2025. The resolution also allows an additional 15-day extension for the submission of consolidated financial statements from companies that include affiliated insurance entities. The FRA noted that the extension is intended to give insurance sector entities sufficient time to prepare financial statements in accordance with the rules and requirements issued under the Unified Insurance Law. The decision also takes into account companies' need for a revised timeframe following the adoption of resolution No. 183 of 2024, which set the start and end dates for financial periods and required quarterly financial statements starting 2025. These quarterly reports must include comparative figures from the same period in the previous year and comply with Egyptian accounting standard No. 50 on insurance contracts. They are to be reviewed and submitted with a limited review report from the company's auditor. © 2020-2023 Arab Finance For Information Technology. All Rights Reserved. Provided by SyndiGate Media Inc. (
Yahoo
12 hours ago
- Business
- Yahoo
Calculating The Intrinsic Value Of Nordwest Handel AG (FRA:NWX)
The projected fair value for Nordwest Handel is €18.16 based on Dividend Discount Model With €20.60 share price, Nordwest Handel appears to be trading close to its estimated fair value The average discount for Nordwest Handel's competitorsis currently 52% How far off is Nordwest Handel AG (FRA:NWX) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to today's value. The Discounted Cash Flow (DCF) model is the tool we will apply to do this. Models like these may appear beyond the comprehension of a lay person, but they're fairly easy to follow. Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. We have to calculate the value of Nordwest Handel slightly differently to other stocks because it is a trade distributors company. Instead of using free cash flows, which are hard to estimate and often not reported by analysts in this industry, dividends per share (DPS) payments are used. Unless a company pays out the majority of its FCF as a dividend, this method will typically underestimate the value of the stock. The 'Gordon Growth Model' is used, which simply assumes that dividend payments will continue to increase at a sustainable growth rate forever. For a number of reasons a very conservative growth rate is used that cannot exceed that of a company's Gross Domestic Product (GDP). In this case we used the 5-year average of the 10-year government bond yield (1.3%). The expected dividend per share is then discounted to today's value at a cost of equity of 6.8%. Relative to the current share price of €20.6, the company appears around fair value at the time of writing. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind. Value Per Share = Expected Dividend Per Share / (Discount Rate - Perpetual Growth Rate) = €1.0 / (6.8% – 1.3%) = €18.2 Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Nordwest Handel as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.8%, which is based on a levered beta of 1.271. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. View our latest analysis for Nordwest Handel Strength Currently debt free. Dividend is in the top 25% of dividend payers in the market. Weakness Earnings declined over the past year. Current share price is above our estimate of fair value. Opportunity NWX's financial characteristics indicate limited near-term opportunities for shareholders. Lack of analyst coverage makes it difficult to determine NWX's earnings prospects. Threat Paying a dividend but company has no free cash flows. Although the valuation of a company is important, it is only one of many factors that you need to assess for a company. DCF models are not the be-all and end-all of investment valuation. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. For Nordwest Handel, we've compiled three further items you should look at: Risks: For instance, we've identified 3 warning signs for Nordwest Handel that you should be aware of. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing! Other Environmentally-Friendly Companies: Concerned about the environment and think consumers will buy eco-friendly products more and more? Browse through our interactive list of companies that are thinking about a greener future to discover some stocks you may not have thought of! PS. Simply Wall St updates its DCF calculation for every German stock every day, so if you want to find the intrinsic value of any other stock just search here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
12 hours ago
- Business
- Cision Canada
BIOVAXYS ANNOUNCES AMENDED LIFE OFFERING
VANCOUVER, BC, June 20, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (" BioVaxys" or the " Company") announces that it has amended the terms of its brokered private placement LIFE financing (the " Offering") previously announced on May 30, 2025, and filed an amended offering document (the " Amended Offering Document"). The Amended Offering Document updates the exercise price of the common share purchase warrant that forms part of the units (" Units") being offered by the Company from a post-consolidation exercise price of $0.60 to a post-consolidation exercise price of $0.50. As previously announced, the Company intends to consolidate the common shares of the Company (the " Common Shares") on the basis of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the " Consolidation"), and complete a concurrent Offering consisting of a minimum of 5,714,285 Units at a post-Consolidation price of $0.35 per Unit for minimum gross proceeds of $2,000,000 and a maximum of 8,571,428 Units at a post-Consolidation price of $0.35 per Unit for maximum gross proceeds of up to $3,000,000. Each Unit will consist of one (1) post-Consolidation common share in the capital of the Company (each, a " Post-Consolidation Common Share") and one (1) Post-Consolidation Common Share purchase warrant (each, a " Post-Consolidation Warrant"). Each Post-Consolidation Warrant will entitle the holder thereof to purchase one Post-Consolidation Common Share at a post-Consolidation price of $0.50 for a period of 36 months from the closing date of the Offering. Closing of the Offering is anticipated to occur on or about June 30, 2025, or such other date as the Company may agree upon provided such date is on or before July 14, 2025. Closing of the Offering is subject to the satisfaction of certain conditions, including, but not limited to, acceptance by the CSE. The Company intends to use the net proceeds raised from the Offering for research and development, general corporate purposes and working capital. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions (" NI 45-106"), the Units issuable under the Offering will be offered for sale to purchasers in all provinces and territories of Canada, except Quebec, pursuant to the listed issuer financing exemption (" LIFE") under Part 5A of NI 45-106. The securities to be issued pursuant to the sale of the Units under the Offering will not be subject to resale restrictions in accordance with applicable Canadian securities laws. There is an Amended Offering Document dated June 18, 2025, related to the Offering that can be accessed under the Company's profile at and on the Company's website at Prospective investors should read this offering document before making an investment decision. This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform for refractive late-stage ovarian cancer. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on the OTC Markets (OTCQB marketplace). For more information, visit and connect with us on X and LinkedIn. ON BEHALF OF THE BOARD Signed " James Passin" James Passin, Chief Executive Officer Phone: +1 740 358 0555 Cautionary Statements on Forward Looking Information This news release includes certain "forward-looking information" and "forward-looking statements" (collectively " forward-looking statements") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, the proposed Consolidation, including the ratio thereof and timing thereof, and the Offering, including the size and use of proceeds, and the timing and ability of the Company to close the Offering, including obtaining approval of the Offering from the CSE. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by BioVaxys, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the ability of the Company to complete the Consolidation and the Offering on the terms proposed or at all, and the ability to obtain necessary approvals, including the approval of the CSE. BioVaxys does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws.
Yahoo
a day ago
- General
- Yahoo
How to Tell if You Qualify for Social Security Spousal Benefits
Spousal benefits allow you to claim up to 50% of your spouse's Social Security benefit. Divorce doesn't prevent you from claiming spousal benefits, provided you were married long enough and are currently single. Same-sex spouses and ex-spouses are eligible to collect spousal benefits. The $23,760 Social Security bonus most retirees completely overlook › If, historically, you've been the lower-earning spouse, you may plan to claim spousal Social Security benefits. As long as you wait until your full retirement age (FRA) to claim them, spousal benefits can provide you with Social Security benefits of up to 50% of the amount your spouse is scheduled to receive at FRA. If you're not quite sure if you qualify, here's how you can know for certain. You must be legally married to someone who has earned enough work credits to be eligible for Social Security benefits or be divorced from an eligible recipient (more on this in a moment). You must be married for at least one year before applying for benefits. If your spouse is deceased, you must have been married for at least nine months before their death. If you're divorced, you may still qualify for spousal benefits based on your ex's work record. To qualify, the marriage must have lasted at least 10 years, and your ex-spouse must be eligible for Social Security benefits. In addition, you must be currently unmarried (it's OK if your last marriage ended in divorce). Your spouse must be eligible for benefits, either due to earning enough work credits or by being retired, disabled, or deceased. For you to collect spousal benefits, your spouse must have applied for their own Social Security benefits. If your spouse has already applied for benefits, you can apply for yours as early as age 62. However, since the full retirement age is typically between 66 and 67, claiming benefits at age 62 is considered early, and your monthly benefits will be permanently reduced. There are a couple of exceptions to this rule. You can qualify for spousal benefits at any age if: You are caring for a child under the age of 16. You are caring for a disabled child, and that child is entitled to receive benefits based on your spouse's work record. The rules and benefits awarded are the same for same-sex spouses as for any other married couple due to the Supreme Court's 2015 decision recognizing marriage equality. Depending on the state in which you live, you may qualify for benefits if you are (or were) a registered domestic partner or in a civil union or common-law marriage. While you may feel as though you have to jump through hoops, it can be beneficial to work with the Social Security Administration (SSA) to determine which laws apply in your state. If applying for Social Security spousal benefits seems a little intimidating, it may help to keep these tips in mind: The application process is not complicated. You can apply online, by phone, or in person at your local SSA office. Have your marriage certificate and other relevant documents ready to streamline the application process. Before deciding when to claim benefits, consider your health, family history of life expectancy, and how much longer you wish to work. The right time to claim often comes down to how long you need the money you've saved for retirement to last. If you still feel like you're in your 20s or 30s, applying for Social Security benefits can seem a bit surreal. However, for anyone fortunate enough to live long enough, the day does eventually arrive. When it does, your goal is to ensure you receive the largest monthly benefit possible. If you're like most Americans, you're a few years (or more) behind on your retirement savings. But a handful of little-known could help ensure a boost in your retirement income. One easy trick could pay you as much as $23,760 more... each year! Once you learn how to maximize your Social Security benefits, we think you could retire confidently with the peace of mind we're all after. Join Stock Advisor to learn more about these Motley Fool has a disclosure policy. How to Tell if You Qualify for Social Security Spousal Benefits was originally published by The Motley Fool
